Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03IDK
|
||||
| Former ID |
DIB002091
|
||||
| Drug Name |
CEP-18050
|
||||
| Synonyms |
ALK inhibitors (anaplastic large cell lymphoma); CEP-18050; ALK inhibitors (anaplastic large cell lymphoma), Cephalon; Alk inhibitors (cancer), Cephalon
|
||||
| Indication | Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] | Investigative | [1] | ||
| Company |
Cephalon Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1c(c(cc2c1CCN(CC2)CC(=O)N(C)C)OC)Nc1nc(c(cn1)Cl)Nc1c(c<br />c(cc1)N1CCOCC1)OC
|
||||
| Target and Pathway | |||||
| Target(s) | ALK tyrosine kinase receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Non-small cell lung cancer | ||||
| WikiPathways | Differentiation Pathway | ||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.